ZK-EPO: Interim Phase I data

In an ongoing dose-escalation Phase I trial in 52 patients, 30-minute IV infusions of ZK-EPO once every 3 weeks was well tolerated and anti-tumor activity was observed. MTD has not been reached and DL...